Suppr超能文献

用于癌症诊断和治疗的基于CRISPR的前沿策略。

State of the art CRISPR-based strategies for cancer diagnostics and treatment.

作者信息

Di Carlo Emma, Sorrentino Carlo

机构信息

Department of Medicine and Sciences of Aging, "G. d'Annunzio University" of Chieti- Pescara, Via dei Vestini, Chieti, 66100, Italy.

Anatomic Pathology and Immuno-Oncology Unit, Center for Advanced Studies and Technology (CAST), "G. d'Annunzio" University of Chieti-Pescara, Via L. Polacchi 11, Chieti, 66100, Italy.

出版信息

Biomark Res. 2024 Dec 18;12(1):156. doi: 10.1186/s40364-024-00701-x.

Abstract

Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology is a groundbreaking and dynamic molecular tool for DNA and RNA "surgery". CRISPR/Cas9 is the most widely applied system in oncology research. It is a major advancement in genome manipulation due to its precision, efficiency, scalability and versatility compared to previous gene editing methods. It has shown great potential not only in the targeting of oncogenes or genes coding for immune checkpoint molecules, and in engineering T cells, but also in targeting epigenomic disturbances, which contribute to cancer development and progression. It has proven useful for detecting genetic mutations, enabling the large-scale screening of genes involved in tumor onset, progression and drug resistance, and in speeding up the development of highly targeted therapies tailored to the genetic and immunological profiles of the patient's tumor. Furthermore, the recently discovered Cas12 and Cas13 systems have expanded Cas9-based editing applications, providing new opportunities in the diagnosis and treatment of cancer. In addition to traditional cis-cleavage, they exhibit trans-cleavage activity, which enables their use as sensitive and specific diagnostic tools. Diagnostic platforms like DETECTR, which employs the Cas12 enzyme, that cuts single-stranded DNA reporters, and SHERLOCK, which uses Cas12, or Cas13, that specifically target and cleave single-stranded RNA, can be exploited to speed up and advance oncological diagnostics. Overall, CRISPR platform has the great potential to improve molecular diagnostics and the functionality and safety of engineered cellular medicines. Here, we will emphasize the potentially transformative impact of CRISPR technology in the field of oncology compared to traditional treatments, diagnostic and prognostic approaches, and highlight the opportunities and challenges raised by using the newly introduced CRISPR-based systems for cancer diagnosis and therapy.

摘要

成簇规律间隔短回文重复序列(CRISPR)技术是一种用于DNA和RNA“手术”的开创性且充满活力的分子工具。CRISPR/Cas9是肿瘤学研究中应用最广泛的系统。与以前的基因编辑方法相比,它在基因组操作方面取得了重大进展,因为它具有精确性、高效性、可扩展性和多功能性。它不仅在靶向癌基因或编码免疫检查点分子的基因以及工程化T细胞方面显示出巨大潜力,而且在靶向导致癌症发生和发展的表观基因组紊乱方面也具有潜力。事实证明,它可用于检测基因突变,能够大规模筛选参与肿瘤发生、发展和耐药性的基因,并加速开发针对患者肿瘤的基因和免疫特征的高度靶向治疗方法。此外,最近发现的Cas12和Cas13系统扩展了基于Cas9的编辑应用,为癌症的诊断和治疗提供了新机会。除了传统的顺式切割外,它们还表现出反式切割活性,这使其能够用作灵敏且特异的诊断工具。像DETECTR这样使用Cas12酶切割单链DNA报告分子的诊断平台,以及使用Cas12或Cas13特异性靶向并切割单链RNA的SHERLOCK诊断平台,可用于加速和推进肿瘤学诊断。总体而言,CRISPR平台在改善分子诊断以及工程化细胞药物的功能和安全性方面具有巨大潜力。在这里,我们将强调与传统治疗、诊断和预后方法相比,CRISPR技术在肿瘤学领域可能产生的变革性影响,并突出使用新引入的基于CRISPR的系统进行癌症诊断和治疗所带来的机遇和挑战。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/846b/11657220/819b1f3398a9/40364_2024_701_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验